MNPR Monopar Therapeutics Inc.

Biotech Analyst Ratings

Latest News

1. 12 May 2022 Monopar Therapeutics Reports First Quarter 2022 Financial Results and Recent Program Developments

   Validive^® Phase 2b/3 VOICE Trial Continues Enrolling Patients Toward Interim
   Camsirubicin Phase 1b Dose-Escalation Trial Clears 3^rd Dose Level, Now Enrolling 4^th

   WILMETTE, Ill., May 12, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (NASDAQ:MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced first quarter 2022 financial results and summarized recent program developments.

   Recent Program Developments

   Validive – International Phase 2b/3 VOICE Clinical Trial, Actively Recruiting

   • The VOICE trial continues to enroll patients and add additional clinical sites, with the interim analysis…

   View Full Article
2. 24 March 2022 Monopar Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Developments

   Validive^® Phase 2b/3 VOICE Trial Continues Adding Sites in the U.S. and Europe
   

   Camsirubicin Phase 1b Dose-Esclation Trial Clears 2nd Dose Level and is Now Enrolling 3rd Dose-Level Cohort

   WILMETTE, Ill., March 24, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (NASDAQ:MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced fourth quarter and full-year 2021 financial results and summarized recent program developments.

   Recent Program Developments and Highlights

   Validive – International Phase 2b/3 VOICE Clinical Trial, Actively Recruiting

   • Validive…

   View Full Article
3. 08 March 2022 Monopar to Present at the 34th Annual Roth Conference and Maxim's 2022 Virtual Growth Conference

   WILMETTE, Ill., March 08, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler Robinson, MD, Monopar's Chief Executive Officer, will present at the 34^th Annual Roth Conference and Maxim's 2022 Virtual Growth Conference.
   

   Presentation Details:

   34^th Annual Roth Conference

   https://www.roth.com/conferences/upcoming-conferences
   Date: March 14, 2022
   Time: 1:30pm Pacific Time
   Location: The Ritz Carlton, Laguna Niguel located in Dana Point, California

   Maxim's 2022 Virtual Growth Conference

   https://www.m-vest.com/home
   Date: March 30, 2022
   Time…

   View Full Article
4. 15 February 2022 Monopar Announces Clinical and Preclinical Program Updates

   • Validive Phase 2b/3 VOICE trial now open at 43 sites; active and enrolling in US and EU

   • Open-label Phase 1b camsirubicin trial: early signs of clinical benefit observed
     

   WILMETTE, Ill., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced program updates across its pipeline and anticipated 2022 highlights.

   Program Developments

   Validive – International Phase 2b/3 VOICE Clinical Trial, Actively Recruiting

   Severe oral mucositis (SOM) is a painful and debilitating ulceration of the mucosal membranes of the mouth caused by the chemoradiotherapy…

   View Full Article
5. 07 January 2022 Monopar to Present at the H.C. Wainwright BioConnect Conference

   WILMETTE, Ill., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler Robinson, MD, Monopar's Chief Executive Officer, will present at the H.C. Wainwright BioConnect Conference. The presentation will be available for on-demand viewing starting on Monday, January 10, 2022 at 7:00am ET.
   
   Presentation Details:

   Date: Monday, January 10, 2022

   Time: 7:00am ET

   Location: Virtual

   https://hcwevents.com/
   
   About Monopar Therapeutics Inc.

   Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary…

   View Full Article